Phathom Pharmaceuticals (PHAT)

• Market cap: $964M
• 1 day: 1.8%
• 5 days: -0.73%
• 1 month: 15.12%
• 3 months: 58.67%
• 6 months: 215.85%
• Year to date: 84.86%
• 1 year: -20.99%
• 5 years: -65.64%
• 10 years: -44.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 427